Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PAVmed Inc. stock logo
PAVM
PAVmed
$1.72
-2.8%
$2.18
$1.60
$9.00
$15.77M0.8564,892 shs30,254 shs
Soliton, Inc. stock logo
SOLY
Soliton
$22.58
$21.55
$7.40
$22.60
$487.66M0.19347,827 shsN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
$3.49
-0.9%
$3.92
$1.03
$5.07
$104.63M2.44180,264 shs44,572 shs
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$65.92
-0.6%
$69.51
$65.91
$100.59
$236.65M0.1226,496 shs22,564 shs
The Westaim Co. stock logo
WEDXF
Westaim
$2.72
$2.67
$2.13
$2.99
$350.34M0.4628,843 shs4,185 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PAVmed Inc. stock logo
PAVM
PAVmed
-5.95%-10.77%-15.53%-24.35%-75.23%
Soliton, Inc. stock logo
SOLY
Soliton
0.00%0.00%0.00%0.00%0.00%
Neuronetics, Inc. stock logo
STIM
Neuronetics
-6.13%-8.09%-26.05%+5.07%+57.85%
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
-1.30%-1.40%-2.71%-20.96%-30.11%
The Westaim Co. stock logo
WEDXF
Westaim
+0.37%+1.87%-0.73%-0.21%+24.77%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
PAVmed Inc. stock logo
PAVM
PAVmed
1.1783 of 5 stars
3.00.00.04.31.10.80.0
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.6374 of 5 stars
3.35.00.00.01.91.70.6
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
2.4002 of 5 stars
0.03.01.74.22.11.71.3
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PAVmed Inc. stock logo
PAVM
PAVmed
2.00
Hold$21.001,120.93% Upside
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.50
Moderate Buy$8.00129.23% Upside
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
N/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/A

Current Analyst Ratings

Latest STIM, PAVM, UTMD, WEDXF, and SOLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/26/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/6/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PAVmed Inc. stock logo
PAVM
PAVmed
$2.45M6.44N/AN/A($3.35) per share-0.51
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/A$1.46 per shareN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
$71.35M1.47N/AN/A$1.18 per share2.96
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$50.22M4.71$6.22 per share10.60$35.35 per share1.86
The Westaim Co. stock logo
WEDXF
Westaim
$8.63M40.60$1.40 per share1.94$3.95 per share0.69

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PAVmed Inc. stock logo
PAVM
PAVmed
-$64.18M-$9.33N/AN/A-2,617.25%N/A-85.99%5/21/2024 (Estimated)
Soliton, Inc. stock logo
SOLY
Soliton
-$14.54M-$1.01N/AN/AN/AN/A-71.85%-62.92%N/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$30.19M-$1.07N/AN/AN/A-42.31%-72.76%-29.25%5/7/2024 (Confirmed)
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$16.64M$4.5714.42N/A33.12%13.53%12.68%7/23/2024 (Estimated)
The Westaim Co. stock logo
WEDXF
Westaim
$183.98M$1.302.09N/A2,132.63%37.84%34.98%5/14/2024 (Estimated)

Latest STIM, PAVM, UTMD, WEDXF, and SOLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.33N/A+$0.33N/AN/AN/A  
3/27/2024Q4 2023
The Westaim Co. stock logo
WEDXF
Westaim
N/A$0.26+$0.26$0.26N/A$1.67 million
3/26/2024Q4 2023
PAVmed Inc. stock logo
PAVM
PAVmed
N/A-$1.57-$1.57-$1.16N/A$1.05 million
3/5/202412/31/2023
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million    
1/30/2024Q4 2023
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
N/A$1.18+$1.18$1.18N/A$12.33 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
PAVmed Inc. stock logo
PAVM
PAVmed
N/AN/AN/AN/AN/A
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$1.201.82%+1.75%26.26%2 Years
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/A

Latest STIM, PAVM, UTMD, WEDXF, and SOLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/6/2024
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
quarterly$0.301.6%3/14/20243/15/20244/3/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PAVmed Inc. stock logo
PAVM
PAVmed
N/A
0.45
0.45
Soliton, Inc. stock logo
SOLY
Soliton
N/A
5.47
5.37
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.73
4.73
4.33
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
N/A
22.56
20.53
The Westaim Co. stock logo
WEDXF
Westaim
N/A
4.23
4.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
PAVmed Inc. stock logo
PAVM
PAVmed
19.93%
Soliton, Inc. stock logo
SOLY
Soliton
35.11%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
69.60%
The Westaim Co. stock logo
WEDXF
Westaim
N/A

Insider Ownership

CompanyInsider Ownership
PAVmed Inc. stock logo
PAVM
PAVmed
12.60%
Soliton, Inc. stock logo
SOLY
Soliton
12.00%
Neuronetics, Inc. stock logo
STIM
Neuronetics
9.80%
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
6.50%
The Westaim Co. stock logo
WEDXF
Westaim
4.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
PAVmed Inc. stock logo
PAVM
PAVmed
1079.17 million8.02 millionOptionable
Soliton, Inc. stock logo
SOLY
Soliton
1421.60 million19.01 millionNot Optionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
20329.98 million27.04 millionOptionable
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
1693.59 million3.36 millionNot Optionable
The Westaim Co. stock logo
WEDXF
Westaim
7128.80 million123.38 millionNot Optionable

STIM, PAVM, UTMD, WEDXF, and SOLY Headlines

SourceHeadline
The Westaim Corporation Reports Q4 and Full Year 2023 ResultsThe Westaim Corporation Reports Q4 and Full Year 2023 Results
businesswire.com - March 27 at 4:25 PM
The Westaim Corporation Recognized on the TSX Venture 50 ListThe Westaim Corporation Recognized on the TSX Venture 50 List
businesswire.com - February 21 at 8:28 AM
Westaim Corp.Westaim Corp.
wsj.com - February 17 at 2:53 PM
DCK ELEVATES BILL BROWN TO PRESIDENTDCK ELEVATES BILL BROWN TO PRESIDENT
finance.yahoo.com - January 17 at 12:21 PM
Westaim (WEDXF) Price Target Increased by 6.07% to 3.93Westaim (WEDXF) Price Target Increased by 6.07% to 3.93
msn.com - November 27 at 5:22 PM
The Westaim GAAP EPS of $0.16The Westaim GAAP EPS of $0.16
seekingalpha.com - November 15 at 12:57 PM
The Westaim Corporation Reports Q3 2023 ResultsThe Westaim Corporation Reports Q3 2023 Results
finance.yahoo.com - November 14 at 4:56 PM
The Westaim GAAP EPS of $0.22, revenue of $35.9MThe Westaim GAAP EPS of $0.22, revenue of $35.9M
seekingalpha.com - August 15 at 9:22 PM
Westaim (WEDXF) Price Target Increased by 15.87% to 3.88Westaim (WEDXF) Price Target Increased by 15.87% to 3.88
msn.com - August 1 at 6:00 PM
Closing Bell: The Westaim Corp flat on Friday (WED)Closing Bell: The Westaim Corp flat on Friday (WED)
theglobeandmail.com - June 24 at 2:58 AM
Westaim Announces Pricing of Secondary Offering of Skyward Specialtys Common StockWestaim Announces Pricing of Secondary Offering of Skyward Specialty's Common Stock
technews.tmcnet.com - June 8 at 1:16 AM
Skyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shrSkyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shr
markets.businessinsider.com - June 8 at 1:16 AM
Westaim Announces Director ResignationWestaim Announces Director Resignation
technews.tmcnet.com - April 25 at 8:25 AM
Closing Bell: The Westaim Corp flat on Monday (WED)Closing Bell: The Westaim Corp flat on Monday (WED)
theglobeandmail.com - April 17 at 8:08 PM
The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50
technews.tmcnet.com - February 21 at 9:55 AM
Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)
nz.finance.yahoo.com - November 13 at 4:45 PM
WEDXF The Westaim CorporationWEDXF The Westaim Corporation
seekingalpha.com - October 1 at 5:43 PM
Is Westaim Corp (WEDXF) Stock a Good Investment?Is Westaim Corp (WEDXF) Stock a Good Investment?
aaii.com - September 6 at 10:24 AM
WEDXF.PK - Westaim Corp | Stock Price & Latest News | ReutersWEDXF.PK - Westaim Corp | Stock Price & Latest News | Reuters
reuters.com - September 3 at 9:42 PM
The Westaim Corporation Reports Q2 2022 ResultsThe Westaim Corporation Reports Q2 2022 Results
apnews.com - August 11 at 3:35 PM
The Westaim Corporation Reports Q1 2022 ResultsThe Westaim Corporation Reports Q1 2022 Results
finance.yahoo.com - May 17 at 11:18 AM
The Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor DayThe Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor Day
finance.yahoo.com - May 3 at 6:13 PM
Westaim earnings preview: what Wall Street is expectingWestaim earnings preview: what Wall Street is expecting
markets.businessinsider.com - April 14 at 10:42 AM
Heres what Wall Street expects from Westaims earnings reportHere's what Wall Street expects from Westaim's earnings report
markets.businessinsider.com - April 6 at 12:30 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

PAVmed logo

PAVmed

NASDAQ:PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Soliton logo

Soliton

NASDAQ:SOLY
Soliton, Inc. is a medical development company, which engages in the development of healthcare technological devices for medical and cosmetic treatments. Its technology platform include Rapid Acoustic Pulse, a device uses rapid pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. The firm is also in the pre-revenue stage with its first products being developed for the removal of tattoos and the reduction of cellulite. The company was founded by Walter V. Klemp and Christopher Capelli on March 27, 2012 and is headquartered in Houston, TX.
Neuronetics logo

Neuronetics

NASDAQ:STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Utah Medical Products logo

Utah Medical Products

NASDAQ:UTMD
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Westaim logo

Westaim

OTCMKTS:WEDXF
The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.